Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Abbott LaboratoriesEli Lilly andNovartisPfizerAbbVie
SymbolNYSE:ABTNYSE:LLYNYSE:NVSNYSE:PFENYSE:ABBV
Price Information
Current Price$123.94$185.92$87.20$37.60$106.89
52 Week RangeBuyBuyHoldHoldBuy
MarketRank™
Overall Score2.42.12.02.32.8
Analysis Score2.42.43.22.11.4
Community Score2.82.82.32.92.9
Dividend Score3.32.52.53.35.0
Ownership Score1.71.70.01.71.7
Earnings & Valuation Score1.91.31.91.33.1
Analyst Ratings
Consensus RecommendationBuyBuyHoldHoldBuy
Consensus Price Target$122.05$196.40$108.50$38.57$115.75
% Upside from Price Target-1.52% downside5.64% upside24.43% upside2.58% upside8.29% upside
Trade Information
Market Cap$219.56 billion$178.30 billion$199.57 billion$209.72 billion$188.64 billion
Beta0.830.370.590.70.84
Average Volume5,157,6864,223,9551,980,39732,094,1747,433,252
Sales & Book Value
Annual Revenue$31.90 billion$22.32 billion$47.50 billion$51.75 billion$33.27 billion
Price / Sales6.887.994.204.055.67
Cashflow$5.56 per share$7.10 per share$7.38 per share$4.19 per share$9.99 per share
Price / Cash22.3126.1911.828.9710.70
Book Value$17.70 per share$2.81 per share$24.53 per share$11.46 per share($5.53) per share
Price / Book7.0066.163.553.28-19.33
Profitability
Net Income$3.69 billion$8.32 billion$11.73 billion$16.27 billion$7.88 billion
EPS$3.24$6.04$5.24$2.95$8.94
Trailing P/E Ratio65.5830.3828.2224.2622.60
Forward P/E Ratio28.3023.3013.3712.298.78
P/E Growth2.061.571.762.791.54
Net Margins10.50%24.01%14.71%17.85%18.16%
Return on Equity (ROE)18.19%166.45%24.39%24.88%439.24%
Return on Assets (ROA)8.29%15.18%10.59%9.32%13.22%
Dividend
Annual Payout$1.80$3.40$2.08$1.56$5.20
Dividend Yield1.45%1.83%2.39%4.15%4.86%
Three-Year Dividend Growth35.85%42.31%13.60%-10.94%84.37%
Payout Ratio55.56%56.29%39.69%52.88%58.17%
Years of Consecutive Dividend Growth49 Years1 Years1 Years1 Years49 Years
Debt
Debt-to-Equity Ratio0.58%3.27%0.49%0.76%5.38%
Current Ratio1.70%1.36%0.91%1.40%0.95%
Quick Ratio1.19%1.06%0.69%1.13%0.81%
Ownership Information
Institutional Ownership Percentage72.58%75.59%9.86%67.36%67.49%
Insider Ownership Percentage1.70%0.09%0.01%0.08%0.09%
Miscellaneous
Employees109,00035,000105,79488,30047,000
Shares Outstanding1.77 billion958.99 million2.29 billion5.58 billion1.76 billion
Next Earnings Date4/20/2021 (Confirmed)4/27/2021 (Confirmed)4/27/2021 (Confirmed)5/4/2021 (Confirmed)4/30/2021 (Confirmed)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
AbbVie and Pfizer lead rheumatoid arthritis digital marketing space in Australia - BSA bureauAbbVie and Pfizer lead rheumatoid arthritis digital marketing space in Australia - BSA bureau
biospectrumasia.com - April 16 at 9:56 AM
A Dividend Aristocrat On Sale: AbbVie - Seeking AlphaA Dividend Aristocrat On Sale: AbbVie - Seeking Alpha
seekingalpha.com - April 15 at 6:07 PM
Trending: AbbVie Stock Takes Hit From FDAs Extra-Cautious Approach to Drug Approval - Dividend.comTrending: AbbVie Stock Takes Hit From FDA's Extra-Cautious Approach to Drug Approval - Dividend.com
dividend.com - April 15 at 8:06 AM
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatchAbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
marketwatch.com - April 14 at 8:44 PM
Got $1,000? 2 Dirt-Cheap Value Stocks You Can Buy Right NowGot $1,000? 2 Dirt-Cheap Value Stocks You Can Buy Right Now
finance.yahoo.com - April 14 at 3:43 PM
Should AbbVie Be Worried About Rinvoq? - Motley FoolShould AbbVie Be Worried About Rinvoq? - Motley Fool
fool.com - April 14 at 10:42 AM
Should AbbVie Be Worried About Rinvoq?Should AbbVie Be Worried About Rinvoq?
finance.yahoo.com - April 14 at 10:42 AM
AbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for April 14, 2021 - NasdaqAbbVie Inc. (ABBV) Ex-Dividend Date Scheduled for April 14, 2021 - Nasdaq
nasdaq.com - April 14 at 12:41 AM
Insights on the CNS Therapeutics Global Market to 2025 - Featuring AbbVie, Alkermes and Allergan Among OthersInsights on the CNS Therapeutics Global Market to 2025 - Featuring AbbVie, Alkermes and Allergan Among Others
finance.yahoo.com - April 13 at 7:40 PM
AbbVie encourages women to Talk Fibroids online—especially with doctor visits down - FiercePharmaAbbVie encourages women to 'Talk Fibroids' online—especially with doctor visits down - FiercePharma
fiercepharma.com - April 13 at 2:29 PM
A Short Delay Is Still Bad News for AbbVie - Motley FoolA Short Delay Is Still Bad News for AbbVie - Motley Fool
fool.com - April 13 at 2:29 PM
A Short Delay Is Still Bad News for AbbVieA Short Delay Is Still Bad News for AbbVie
finance.yahoo.com - April 13 at 2:29 PM
Taking It Easy Before EarningsTaking It Easy Before Earnings
finance.yahoo.com - April 13 at 2:29 PM
AbbVie: Buy The Humira Fear And Profit - Seeking AlphaAbbVie: Buy The Humira Fear And Profit - Seeking Alpha
seekingalpha.com - April 11 at 12:55 PM
4 Green Flags for AbbVie in 2021 - Motley Fool4 Green Flags for AbbVie in 2021 - Motley Fool
fool.com - April 11 at 7:39 AM
4 Green Flags for AbbVie in 20214 Green Flags for AbbVie in 2021
finance.yahoo.com - April 11 at 7:39 AM
AbbVie presents applications to FDA and EMA for approval of SKYRIZI in psoriatic arthritis - Pharmaceutical Business review - Pharmaceutical Business ReviewAbbVie presents applications to FDA and EMA for approval of SKYRIZI in psoriatic arthritis - Pharmaceutical Business review - Pharmaceutical Business Review
pharmaceutical-business-review.com - April 11 at 12:40 AM
Better Value Stock: AbbVie or Viatris?Better Value Stock: AbbVie or Viatris?
finance.yahoo.com - April 10 at 9:39 AM
2 Dividend Stocks With Great Potential: ViacomCBS And AbbVie - Seeking Alpha2 Dividend Stocks With Great Potential: ViacomCBS And AbbVie - Seeking Alpha
seekingalpha.com - April 9 at 1:16 PM
Pharma Stock Roundup: FDA Decision Delays for PFE, LLY, ABBV, AZN Vaccine WoesPharma Stock Roundup: FDA Decision Delays for PFE, LLY, ABBV, AZN Vaccine Woes
finance.yahoo.com - April 9 at 1:16 PM
Dont Race Out To Buy AbbVie Inc. (NYSE:ABBV) Just Because Its Going Ex-Dividend - Yahoo FinanceDon't Race Out To Buy AbbVie Inc. (NYSE:ABBV) Just Because It's Going Ex-Dividend - Yahoo Finance
finance.yahoo.com - April 9 at 8:15 AM
Dont Race Out To Buy AbbVie Inc. (NYSE:ABBV) Just Because Its Going Ex-DividendDon't Race Out To Buy AbbVie Inc. (NYSE:ABBV) Just Because It's Going Ex-Dividend
finance.yahoo.com - April 9 at 8:15 AM
The Zacks Analyst Blog Highlights: ServiceNow, AbbVie and AppleThe Zacks Analyst Blog Highlights: ServiceNow, AbbVie and Apple
finance.yahoo.com - April 9 at 8:15 AM
Opioid Judge Withdraws After AbbVie Elevates His Atty Sister - Law360Opioid Judge Withdraws After AbbVie Elevates His Atty Sister - Law360
law360.com - April 9 at 12:33 AM
AbbVie Inc. stock rises Thursday, outperforms market - MarketWatchAbbVie Inc. stock rises Thursday, outperforms market - MarketWatch
marketwatch.com - April 8 at 7:28 PM
AbbVie (NYSE:ABBV) Price Target Raised to $144.00 at SVB LeerinkAbbVie (NYSE:ABBV) Price Target Raised to $144.00 at SVB Leerink
marketbeat.com - March 30 at 8:20 AM
3 High Dividend Large Caps Worth Buying3 High Dividend Large Caps Worth Buying
marketbeat.com - February 10 at 1:43 PM
Get Ready To See AbbVie Stock Back At All Time HighsGet Ready To See AbbVie Stock Back At All Time Highs
marketbeat.com - February 4 at 8:52 AM
AbbVie (NYSE:ABBV) Is a Classic Buy the Dip CandidateAbbVie (NYSE:ABBV) Is a Classic Buy the Dip Candidate
marketbeat.com - February 1 at 11:21 AM
Three High-Yield Dividend Stocks For 2021 And Beyond (ABBV)Three High-Yield Dividend Stocks For 2021 And Beyond (ABBV)
marketbeat.com - December 29 at 8:39 AM
DateCompanyBrokerageAction
4/15/2021Abbott LaboratoriesAtlantic SecuritiesInitiated Coverage
3/17/2021Abbott LaboratoriesRaymond JamesBoost Price Target
1/28/2021Abbott LaboratoriesWells Fargo & CompanyBoost Price Target
1/28/2021Abbott LaboratoriesCowenBoost Price Target
1/28/2021Abbott LaboratoriesCredit Suisse GroupBoost Price Target
1/28/2021Abbott LaboratoriesMorgan StanleyBoost Price Target
1/28/2021Abbott LaboratoriesSVB LeerinkBoost Price Target
1/28/2021Abbott LaboratoriesBTIG ResearchUpgrade
10/22/2020Abbott LaboratoriesJefferies Financial GroupBoost Price Target
10/9/2020Abbott LaboratoriesJPMorgan Chase & Co.Boost Price Target
9/11/2020Abbott LaboratoriesWolfe ResearchInitiated Coverage
9/2/2020Abbott LaboratoriesThe Goldman Sachs GroupSet Price Target
8/28/2020Abbott LaboratoriesCitigroupBoost Price Target
3/22/2021Eli Lilly andTruist SecuritiesBoost Price Target
2/1/2021Eli Lilly andMizuhoBoost Price Target
2/1/2021Eli Lilly andBarclaysBoost Price Target
1/22/2021Eli Lilly andBank of AmericaBoost Price Target
11/10/2020Eli Lilly andSanford C. BernsteinInitiated Coverage
9/29/2020Eli Lilly andBerenberg BankInitiated Coverage
6/16/2020Eli Lilly andGuggenheimUpgrade
3/23/2021NovartisSociete GeneraleReiterated Rating
3/16/2021NovartisArgusReiterated Rating
1/15/2021NovartisDeutsche Bank AktiengesellschaftInitiated Coverage
11/25/2020NovartisUBS GroupReiterated Rating
9/23/2020NovartisOddo BhfDowngrade
4/7/2021PfizerRoyal Bank of CanadaInitiated Coverage
2/3/2021PfizerDZ BankReiterated Rating
11/18/2020AbbVieBMO Capital MarketsInitiated Coverage
(Data available from 4/16/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.